Biotechnology · Puerto Rico, USA

Precision medicine built on protein biomarkers.

Omics Global Solutions develops and commercializes diagnostic and prognostic tests based on protein biomarkers, so physicians can act before disease advances.

Network of proteins with highlighted biomarkers
About Omics

A platform for omics-based diagnostics

Omics Global Solutions (OGS) was founded to develop and commercialize products from the omics sciences, such as proteomics, through innovative projects that improve the lives of patients and the work of medical professionals.

Based in Puerto Rico, its first milestone is the development, manufacture and commercialization of INNOVATIO-ND2, a predictive test based on protein biomarkers that identifies the risk of diabetic kidney disease.

Mission

To develop and commercialize clinical prognostic products based on novel scientific models that address the unmet needs of physicians and patients, with high quality standards, extensive commercial experience in Latin America and direct ties to the United States.

Vision

To be a commercially successful company introducing innovative diagnostics that help health professionals start early therapeutic approaches that save lives, and to rank among the fastest-growing biotechnology companies in Latin America and the United States by 2030.

Our product

INNOVATIO-ND2

A predictive test based on protein biomarkers that delivers, in one report, a diagnosis of diabetic kidney disease and the risk of developing it, or how fast it is progressing, up to 4 years in advance.

Diabetic kidney disease is among the most serious and costly complications of type 2 diabetes because of its link to dialysis. Our portfolio focuses on ELISA assays and other platforms that provide diagnosis and prognosis based on novel biomarkers.

CPT 0385U · Covered by Traditional Medicare, MCS and MMM in Puerto Rico

Visit innovatio-nd2.com
Kidney drawn as a network of molecules with the biomarkers ApoA4, CD5L and IGFBP3
Our team

Leadership

Luben Ron

Luben Ron

Co-Founder and CEO

Luben is Co-Founder and CEO of Omics Global Solutions, where since 2016 he has led the commercial strategy and international expansion of the diagnostic portfolio. For more than 20 years before that, he led brands and business units at Novartis, Nycomed (now Takeda) and Baxter across Venezuela, Central America, the Caribbean and Puerto Rico. At Baxter he was Regional Renal Line Manager for Northern Latin America, overseeing dialysis and renal prevention programs, and led the Baxter–Gambro integration for the region. He has taken part in more than 10 product launches and was recognized as Business Unit Manager of the Year (Novartis, 2005) and with the ELITE Award for best Regional Marketing Manager (Baxter, 2014). He holds an MBA in Marketing from Edinburgh Business School (Heriot-Watt University) and trained as an Industrial Administrator (Industriekaufmann) in the German–Venezuelan dual program.

LinkedIn →
Horacio Serrano, PhD

Horacio Serrano, PhD

Co-Founder and Scientific Director

Dr. Serrano is Co-Founder and Scientific Director of Omics Global Solutions. He holds a PhD in Molecular Biology, specializing in Quantitative Proteomics, from the Universidad Autónoma de Madrid, an MS in Environmental Health from the UPR Medical Sciences Campus and a BS in Industrial Microbiology from UPR Arecibo. He is a Professor at the UPR School of Medicine, where he founded and directs the Clinical Proteomics Laboratory at the Comprehensive Cancer Center. The laboratory identifies new biomarkers by mass spectrometry and confirms them with ELISA assays, including in patients with type 2 diabetes. He has collaborated on research in cardiovascular disease, HIV, Alzheimer's disease and cancer, and served as Dean of Academic Affairs at UPR Utuado.

LinkedIn →
Eric Miranda Valentín, DrPH

Eric Miranda Valentín, DrPH

Quality Assurance Leader

Dr. Miranda holds a Doctor of Public Health in Environmental Health (DrPH, 2023) and a Master of Public Health in Biostatistics (MPH, 2016) from the University of Puerto Rico, and a BS in Chemistry from UPR Cayey. For 14 years he worked as a chemist at Schering-Plough and Johnson & Johnson in Puerto Rico, leading analytical testing, validations, data review for product release and GMP programs. Since 2011 he has been a research assistant in quantitative proteomics and biostatistics at the UPR Medical Sciences Campus, where he supported the development of a biomarker-based prognostic test for patients with diabetes. He is a professor at Ana G. Méndez University and associate editor of the Puerto Rico Health Sciences Journal.